US 12,128,035 B2
Activating pyruvate kinase R
Anna Ericsson, Shrewsbury, MA (US); Neal Green, Newton, MA (US); Gary Gustafson, Ridgefield, CT (US); David R. Lancia, Jr., Boston, MA (US); Gary Marshall, Watertown, MA (US); Lorna Mitchell, Cambridge (NZ); David Richard, Littleton, MA (US); Zhongguo Wang, Lexington, MA (US); Sanjeev Forsyth, Milton, MA (US); Patrick F. Kelly, Concord, MA (US); Madhu Mondal, Winchester, MA (US); Maria Ribadeneira, Cambridge, MA (US); and Patricia Schroeder, Somerville, MA (US)
Assigned to Novo Nordisk Health Care AG, Zurich (CH)
Filed by Novo Nordisk Health Care AG, Zurich (CH)
Filed on Mar. 18, 2022, as Appl. No. 17/698,505.
Claims priority of provisional application 63/163,362, filed on Mar. 19, 2021.
Prior Publication US 2022/0304987 A1, Sep. 29, 2022
Int. Cl. A61K 31/436 (2006.01); A61P 9/00 (2006.01)
CPC A61K 31/436 (2013.01) [A61P 9/00 (2018.01)] 21 Claims
 
1. A method of treating sickle cell disease in a patient, the method comprising repeatedly administering a therapeutically effective amount of Compound 1 to the patient once per day (QD):

OG Complex Work Unit Chemistry